PharmaPoint: Healthcare-Associated Gram-Negative Infections - Global Drug Forecast and Market Analysis to 2026

News provided by

Nov 07, 2017, 02:45 ET

LONDON, Nov. 7, 2017 /PRNewswire/ --

Download the full report: https://www.reportbuyer.com/product/5175851

Summary
Bacterial infections represent a frequent occurrence in humans. Fortunately, a majority of these infections are successfully eliminated by the native and adaptive immune system. The majority of remaining infections that do require medical assistance can be addressed by physicians outside the hospital setting using a set of generic antibiotics commonly prescribed throughout the seven major markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan).

Global marketplace for healthcare-associated infections (HAIs) caused by Gram-negative bacteria-which, for the purpose of this report, consist of the catheter-associated urinary tract infections (CAUTI), central-line-associated bloodstream infections (CLABSI), hospital-associated pneumonia (HAP), ventilator-associated pneumonia (VAP), and surgical site infections (SSI) leading to intra-abdominal infections (IAI), and are caused by either Acinetobacter baumannii, Enterobacter spp, Escherichia coli, Klebsiella spp, or Pseudomonas aeruginosa was worth approximately US$1.3B in 2016.

It is expected that the market will exceed $3.6B in sales by 2026, at a Compound Annual Growth Rate (CAGR) of 10.6% from 2016-2026. These sales are projected to originate predominantly from the US, followed by Germany and France. This growth will be dominated by the launch of multiple pipeline products, which will contribute a combined 73% of the sales in 2026.

The current antibiotic pipeline is dominated by derivatives of commonly used scaffolds and combinations of beta-lactam antibiotics with beta-lactamases. However, the early stage pipeline includes novel approaches for new scaffolds and alternative approaches to combat resistance in Gram-negative bacteria, although most are currently in pre-clinical development.

The report "PharmaPoint: Healthcare-Associated Gram-Negative Infections - Global Drug Forecast and Market Analysis to 2026", provides the overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Particularly, this report provides the following -
- Topline market revenue from 2016-2026 for HAIs caused by Gram-negative bacteria. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global therapeutics market for HAIs caused by Gram-negative bacteria. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Merck & Co, Pfizer, The Medicines Company, Shionogi & Co Ltd, Tetraphase Pharmaceuticals Inc, MerLion Pharmaceuticals Pte Ltd, Achaogen, Aridis Pharmaceuticals, MedImmune LLC, Allergan.

Scope
- Overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline market revenue from 2016-2026 for HAIs caused by Gram-negative bacteria. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global therapeutics market for HAIs caused by Gram-negative bacteria. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global therapeutics market for HAIs caused by Gram-negative bacteria.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the therapeutics market for HAIs caused by Gram-negative bacteria in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Download the full report: https://www.reportbuyer.com/product/5175851

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com